Ad5-yCD/mutTKSR39rep-hIL12

AXP000048.1 · Oncolytic virus

Platform
adenovirus (Ad5, replication-competent, IL-12-armed)
Originator
Henry Ford Health
Sponsor
Henry Ford Health

Names

NameTypeSource
Ad5-yCD/mutTKSR39rep-hIL12preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (yCD/mutTKSR39rep-hIL12)
Replication
replicating
Modifications
replication-competent Ad5 carrying the suicide-gene fusion plus human IL-12
Transgenes
yCD/mutTK(SR39) suicide-gene fusion, IL12A, IL12B
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C123930

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03281382Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic CancerCompletedPhase 12017-07-012019-05-2812Metastatic Pancreatic Cancer
NCT02555397Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate CancerCompletedPhase 12015-082019-06-1615Prostate Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37713401A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.PloS one2023cited by trial NCT02555397

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA160289Gene Therapy and Radiation Therapy for Prostate CancerHENRY FORD HEALTH SYSTEMFREYTAG, SVEND O2012–2016name in abstract: Ad5-yCD/mutTKSR39rep-hIL12

Notes

Third-generation Henry Ford construct: the suicide-gene fusion plus human IL-12. Phase I trials in prostate cancer (NCT02555397) and metastatic pancreatic cancer (NCT03281382).

How to cite

Ad5-yCD/mutTKSR39rep-hIL12 (AXP000048.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000048.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.